# Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

> **NCT02596243** · PHASE2 · UNKNOWN · sponsor: **Genexine, Inc.** · enrollment: 134 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia

## Interventions

- **BIOLOGICAL:** GX-188E
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02596243
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2018-03
- **Final completion:** 2018-08
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596243, "Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02596243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*